Company Profile

PharmaEssentia Corporation, a biopharmaceutical company engages in medicine discovery, supplements in developing specialty pharmaceutical reagents, API, and new drug patterns developments in the Americas, Europe, Asia, and Taiwan. Its products include BESREMi, an interferon therapy indicated for polycythemia vera, essential thrombocythemia, PMF, and adult T-cell leukemias. The company also develops Ropeg + anti PD-1; PEG-IL-2 (P11838); PEG-Cytokines; PD-1-IL-2v; ADC; ADCS; NY-ESO-1 TCR-T; and Novel TCR-T for the treatment of solid tumor and immunology. PharmaEssentia Corporation was founded in 1990 and is headquartered in Taipei, Taiwan.

Latest News

How Lisa Su Has Positioned AMD to Be a Big AI Winner and Why the Stock Is a Buy

Motley Fool • 07/27/2026

Share buybacks in Ericsson during the period July 20 - July 24, 2026

PR Newswire • 07/27/2026

OTLK Stock Jumps Overnight After FDA Approval Of Wet AMD Drug — Analysts See Nearly 300% Upside

Stocktwits • 07/27/2026

Temenos Named One of World’s Top Fintech Companies by CNBC

GlobeNewswire • 07/27/2026

Emerging markets stare at inflation risks as powerful El Niño looms

Reuters • 07/27/2026